Janett Riega-Torres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Janett Riega-Torres has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Dionicio Angel Galarza-Delgado
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
6 shared publications - Jesus Alberto Cardenas-De la Garza
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
6 shared publications - Lorena Perez-Barbosa
Rheumatology Service of University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
5 shared publications - Cassandra Michele Skinner-Taylor
Rheumatology Service of University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
4 shared publications - Eugenio Salvador Barriga-Maldonado
Department of Rheumatology, University Hospital “Dr. Eleuterio Gonzalez”, Universidad Autónoma de Nuevo León, Monterrey, Mexico
3 shared publications - Jorge Antonio Esquivel-Valerio
Rheumatology Department, University Hospital and Faculty of Medicine, Universidad Autónoma de Nuevo León (UANL), Monterrey, Mexico
3 shared publications
Latest Publications
- Open Access
- 5 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (11) , 7039-7050
Chloroquine and hydroxychloroquine retinopathy in a cohort with rheumatic diseases in Mexico: prevalence, risk factors, and retinopathy patterns
Introduction/objectives To compare chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy prevalence, risk factors, severity, and patterns in a cohort of Hispanic patients with rheumatic diseases in Mexico. Methods Retrospective, cross-sectional study of patients with rheumatic diseases treated with CQ/HCQ who underwent retinopathy screening (from 2014 to 2019) with macular spectral domain optical coherence tomography and automated visual field tests. The most recent screening report was included to define the presence or absence of retinopathy. Results A total of 571 patients were recruited; 27 were excluded due to missing reports. A total of 544 patients were analyzed, 26% (140/544) used CQ, and 74% (404/544) HCQ. Mean age at treatment initiation was 44.9 ± 15.8 years; 95% were female. Retinopathy prevalence was higher with CQ (19%) than HCQ (2%) (P < 0.001). This was consistent in those using antimalarials < 5 years (CQ: 8.5% vs. HCQ: 1.8%; P < 0.007) and those using antimalarials ≥ 5 years (CQ: 33% vs. HCQ: 2.4%; P < 0.001). CQ patients had more years of use at retinopathy diagnosis than HCQ patients (9.0 ± 4.3 vs. 5.1 ± 3.3, P < 0.023). Parafoveal retinopathy pattern was most frequent in patients using CQ (81%) and HCQ (100%), with no isolated perifoveal pattern. Most patients with retinopathy (59%) had a severe grade. In multivariable regression model, CQ was associated with higher odds of retinopathy compared with HCQ (OR, 12.03; 95% CI 4.41–35.74; P < 0.001). Observed independent risk factors for retinopathy were older age at treatment initiation (OR, 1.04; 95% CI 1.00–1.08; P = 0.029) and years of antimalarial use (OR, 1.18; 95% CI 1.09–1.28; P < 0.001). Conclusion CQ poses a higher risk of antimalarial retinopathy than HCQ. Older age at treatment initiation and duration of use were independent risk factors. Parafoveal was the most frequent retinopathy pattern. Key Points • Antimalarial retinopathy prevalence is significantly higher with chloroquine (19%) than with hydroxychloroquine (2%). • Chloroquine use is associated with significantly higher odds of retinopathy compared with hydroxychloroquine (OR, 12.03; 95% CI 4.41–35.74; P < 0.001). • An older age at treatment initiation (OR, 1.04; 95% CI 1.00–1.08; P = 0.029) and years of antimalarial use (OR, 1.18; 95% CI 1.09–1.28; P < 0.001) are independent risk factors for chloroquine/hydroxychloroquine retinopathy. • The most frequently observed antimalarial retinopathy pattern in this cohort of rheumatic patients in Mexico was the parafoveal (85%), with no cases of perifoveal pattern.
- 5 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (11) , 7039-7050
Open AccessChloroquine and hydroxychloroquine retinopathy in a cohort with rheumatic diseases in Mexico: prevalence, risk factors, and retinopathy patterns
Introduction/objectives To compare chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy prevalence, risk factors, severity, and patterns in a cohort of Hispanic patients with rheumatic diseases in Mexico. Methods Retrospective, cross-sectional study of patients with rheumatic diseases treated with CQ/HCQ who underwent retinopathy screening (from 2014 to 2019) with macular spectral domain optical coherence tomography and automated visual field tests. The most recent screening report was included to define the presence or absence of retinopathy. Results A total of 571 patients were recruited; 27 were excluded due to missing reports. A total of 544 patients were analyzed, 26% (140/544) used CQ, and 74% (404/544) HCQ. Mean age at treatment initiation was 44.9 ± 15.8 years; 95% were female. Retinopathy prevalence was higher with CQ (19%) than HCQ (2%) (P < 0.001). This was consistent in those using antimalarials < 5 years (CQ: 8.5% vs. HCQ: 1.8%; P < 0.007) and those using antimalarials ≥ 5 years (CQ: 33% vs. HCQ: 2.4%; P < 0.001). CQ patients had more years of use at retinopathy diagnosis than HCQ patients (9.0 ± 4.3 vs. 5.1 ± 3.3, P < 0.023). Parafoveal retinopathy pattern was most frequent in patients using CQ (81%) and HCQ (100%), with no isolated perifoveal pattern. Most patients with retinopathy (59%) had a severe grade. In multivariable regression model, CQ was associated with higher odds of retinopathy compared with HCQ (OR, 12.03; 95% CI 4.41–35.74; P < 0.001). Observed independent risk factors for retinopathy were older age at treatment initiation (OR, 1.04; 95% CI 1.00–1.08; P = 0.029) and years of antimalarial use (OR, 1.18; 95% CI 1.09–1.28; P < 0.001). Conclusion CQ poses a higher risk of antimalarial retinopathy than HCQ. Older age at treatment initiation and duration of use were independent risk factors. Parafoveal was the most frequent retinopathy pattern. Key Points • Antimalarial retinopathy prevalence is significantly higher with chloroquine (19%) than with hydroxychloroquine (2%). • Chloroquine use is associated with significantly higher odds of retinopathy compared with hydroxychloroquine (OR, 12.03; 95% CI 4.41–35.74; P < 0.001). • An older age at treatment initiation (OR, 1.04; 95% CI 1.00–1.08; P = 0.029) and years of antimalarial use (OR, 1.18; 95% CI 1.09–1.28; P < 0.001) are independent risk factors for chloroquine/hydroxychloroquine retinopathy. • The most frequently observed antimalarial retinopathy pattern in this cohort of rheumatic patients in Mexico was the parafoveal (85%), with no cases of perifoveal pattern.
- Open Access
- 12 November 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 65 (1) , 1-6
Complicated grief following pregnancy loss in women with autoimmune rheumatic diseases: a comparative cross-sectional study
- 12 November 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 65 (1) , 1-6
Open AccessComplicated grief following pregnancy loss in women with autoimmune rheumatic diseases: a comparative cross-sectional study
- 19 June 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (9) , 2453-2460
Construction and validation of a reproductive behavior questionnaire for female patients with rheumatic diseases
Introduction/objectives Active autoimmune rheumatic diseases (ARDs) before conception increase the risk of flares and adverse pregnancy outcomes. We aimed to construct and validate a reproductive behavior questionnaire in Spanish for patients with ARDs to assess their knowledge and their reproductive behavior. Method We constructed and validated a reproductive behavior questionnaire in two phases: (1) a literature review followed by interviews of reproductive-age female patients, and (2) a cross-sectional study to complete validation. Convenience sampling was carried out with 165 female patients: 65 participated in the cross-cultural adaptation phase and 100 in the validation phase. The internal consistency was evaluated by estimating Cronbach’s alpha and tetrachoric correlation coefficients. Values ≥ 0.40 were considered acceptable (p < 0.05). Results The initial instrument included 38 questions. Thematic analysis identified 8 important dimensions or topics, which were combined to create the Rheuma Reproductive Behavior interview questionnaire. A final total of 41 items across 10 dimensions were obtained. The test–retest analysis showed perfect correlations in 34 of the 41 items, moderate in 6 items, and negative in one of the items. The mean age of the patients was 35.65 years (SD 9.02), and the mean time to answer the survey was 13.66 min (SD 7.1). Conclusions The Rheuma Reproductive Behavior questionnaire showed good reliability and consistency capturing patients’ reproductive health knowledge and reproductive behavior. Key Points • We designed and validated a questionnaire to assess reproductive health knowledge and reproductive behavior among female patients with ARDs. • The questionnaire was comprehensible for participants, and showed good reliability and consistency capturing reproductive knowledge and behavior. • This tool may aid in the design of strategies to improve reproductive decision-making for female patients with ARDs.
- 19 June 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (9) , 2453-2460
Construction and validation of a reproductive behavior questionnaire for female patients with rheumatic diseases
Introduction/objectives Active autoimmune rheumatic diseases (ARDs) before conception increase the risk of flares and adverse pregnancy outcomes. We aimed to construct and validate a reproductive behavior questionnaire in Spanish for patients with ARDs to assess their knowledge and their reproductive behavior. Method We constructed and validated a reproductive behavior questionnaire in two phases: (1) a literature review followed by interviews of reproductive-age female patients, and (2) a cross-sectional study to complete validation. Convenience sampling was carried out with 165 female patients: 65 participated in the cross-cultural adaptation phase and 100 in the validation phase. The internal consistency was evaluated by estimating Cronbach’s alpha and tetrachoric correlation coefficients. Values ≥ 0.40 were considered acceptable (p < 0.05). Results The initial instrument included 38 questions. Thematic analysis identified 8 important dimensions or topics, which were combined to create the Rheuma Reproductive Behavior interview questionnaire. A final total of 41 items across 10 dimensions were obtained. The test–retest analysis showed perfect correlations in 34 of the 41 items, moderate in 6 items, and negative in one of the items. The mean age of the patients was 35.65 years (SD 9.02), and the mean time to answer the survey was 13.66 min (SD 7.1). Conclusions The Rheuma Reproductive Behavior questionnaire showed good reliability and consistency capturing patients’ reproductive health knowledge and reproductive behavior. Key Points • We designed and validated a questionnaire to assess reproductive health knowledge and reproductive behavior among female patients with ARDs. • The questionnaire was comprehensible for participants, and showed good reliability and consistency capturing reproductive knowledge and behavior. • This tool may aid in the design of strategies to improve reproductive decision-making for female patients with ARDs.
- 21 February 2021
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (3) , 1765-1768
Mycophenolate mofetil and mycophenolic acid for the treatment of eosinophilic fasciitis: report of two cases and literature review
Eosinophilic fasciitis (EF) is an uncommon autoimmune connective tissue disorder characterized by edema, erythema, and subsequent induration of the extremities. It is commonly treated with corticosteroids but there is no treatment ladder for immunosuppressants or steroid-sparing agents. We report two EF cases treated effectively with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and present a literature review. We performed a MEDLINE search using the keywords ‘eosinophilic fasciitis’, ‘Shulman syndrome’, ‘mycophenolic acid’, or ‘mofetil mycophenolate’, and found 8 articles with 27 cases in which MMF or MPA was used. Twenty-nine cases were reviewed (2 reported herein and 27 from the literature search); all patients received a combination of systemic corticosteroids and MMF. MMF/MPA were given as a steroid-sparing agent in 27 (93.1%), in 1 (3.4%) as adjunctive therapy with other immunosuppressants, and in one, as monotherapy 1 (3.4%). Nineteen had a complete response, 6, a partial response, and 2 were unresponsive to diverse immunomodulators; in 2 cases, the outcome was not reported. MMF and MPA show promising therapeutic results and could be a treatment option to reduce corticosteroid related side effects.
- 21 February 2021
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (3) , 1765-1768
Mycophenolate mofetil and mycophenolic acid for the treatment of eosinophilic fasciitis: report of two cases and literature review
Eosinophilic fasciitis (EF) is an uncommon autoimmune connective tissue disorder characterized by edema, erythema, and subsequent induration of the extremities. It is commonly treated with corticosteroids but there is no treatment ladder for immunosuppressants or steroid-sparing agents. We report two EF cases treated effectively with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and present a literature review. We performed a MEDLINE search using the keywords ‘eosinophilic fasciitis’, ‘Shulman syndrome’, ‘mycophenolic acid’, or ‘mofetil mycophenolate’, and found 8 articles with 27 cases in which MMF or MPA was used. Twenty-nine cases were reviewed (2 reported herein and 27 from the literature search); all patients received a combination of systemic corticosteroids and MMF. MMF/MPA were given as a steroid-sparing agent in 27 (93.1%), in 1 (3.4%) as adjunctive therapy with other immunosuppressants, and in one, as monotherapy 1 (3.4%). Nineteen had a complete response, 6, a partial response, and 2 were unresponsive to diverse immunomodulators; in 2 cases, the outcome was not reported. MMF and MPA show promising therapeutic results and could be a treatment option to reduce corticosteroid related side effects.
- 14 August 2020
- Published by Springer Nature in Rheumatology International
- Vol. 41 (2) , 409-414
Reproductive health counseling and contraceptive use in Mexican women with rheumatic diseases: a cross-sectional study
Background There is an overall increased risk of adverse pregnancy outcomes and maternal morbidity in patients with most autoimmune rheumatic diseases (ARD); outcomes are generally improved when the pregnancy is planned and the disease is in control. Objective The objective of the present study was to describe the sexual and reproductive health characteristics and contraceptive use of Mexican women in childbearing age with ARD. Methods We conducted an observational, cross-sectional, and descriptive study. All non-pregnant childbearing age women with an ARD were invited to participate. A self-administered questionnaire of ten items that included questions about sexuality, use of contraceptive methods, pregnancy desire, and contraceptional counseling was applied. Results A total of 135 women were evaluated. The median age was 33 (25–39) years. Contraceptive use was referred by 49 (71%) of the patients that had sexual activity the last month, while 20 (28.9%) patients denied use. From the patients who had initiated sexual activity (N = 112), 41 (36.6%) did not use any contraceptive method, and 16 (14%) used a method classified as ineffective. The question about contraceptive counseling was answered by 112 patients. Eighty (70.4%) said they had received counseling from health-professional and 64 (57.1%) from their rheumatologist. A total of 57% of the women with teratogenic drugs did not employ a contraception method. Conclusion Contraceptive use and reproductive health counseling are suboptimal in Mexican women with ARD. A high proportion of women taking teratogenic drugs did not employ a highly effective contraceptive method. Strategies to improve reproductive and sexual health are necessary.
- 14 August 2020
- Published by Springer Nature in Rheumatology International
- Vol. 41 (2) , 409-414
Reproductive health counseling and contraceptive use in Mexican women with rheumatic diseases: a cross-sectional study
Background There is an overall increased risk of adverse pregnancy outcomes and maternal morbidity in patients with most autoimmune rheumatic diseases (ARD); outcomes are generally improved when the pregnancy is planned and the disease is in control. Objective The objective of the present study was to describe the sexual and reproductive health characteristics and contraceptive use of Mexican women in childbearing age with ARD. Methods We conducted an observational, cross-sectional, and descriptive study. All non-pregnant childbearing age women with an ARD were invited to participate. A self-administered questionnaire of ten items that included questions about sexuality, use of contraceptive methods, pregnancy desire, and contraceptional counseling was applied. Results A total of 135 women were evaluated. The median age was 33 (25–39) years. Contraceptive use was referred by 49 (71%) of the patients that had sexual activity the last month, while 20 (28.9%) patients denied use. From the patients who had initiated sexual activity (N = 112), 41 (36.6%) did not use any contraceptive method, and 16 (14%) used a method classified as ineffective. The question about contraceptive counseling was answered by 112 patients. Eighty (70.4%) said they had received counseling from health-professional and 64 (57.1%) from their rheumatologist. A total of 57% of the women with teratogenic drugs did not employ a contraception method. Conclusion Contraceptive use and reproductive health counseling are suboptimal in Mexican women with ARD. A high proportion of women taking teratogenic drugs did not employ a highly effective contraceptive method. Strategies to improve reproductive and sexual health are necessary.
- 30 June 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 23 (8) , 1019-1023
Cognitive dysfunction in Sjögren’s syndrome using the Montreal Cognitive Assessment Questionnaire and the Automated Neuropsychological Assessment Metrics: A cross‐sectional study
Aim: To describe the prevalence of cognitive impairment and the most affected cognitive domains, employing the Montreal Cognitive Assessment (MoCA) and the Automated Neuropsychological Assessment Metrics (ANAM) of a Latin American primary Sjögren's syndrome (pSS) cohort, and compare these patients to secondary Sjögren's syndrome (sSS) subjects and controls.Methods: This was a comparative cross‐sectional study of patients with a diagnosis of pSS who fulfilled the American‐European Consensus Group 2002 criteria and/or American College of Rheumatology/European League Against Rheumatism 2016 criteria; clinical information was evaluated prior to cognitive evaluation, which consisted of a single session in which the MoCA and ANAM were applied.Results: A total of 122 subjects were included in the analysis (51 pSS, 20 sSS and 51 controls); mean age of pSS was 56 years (SD 10.4), of which 47 (92.15%) were women. Moderate‐severe cognitive impairment by MoCA was 17% in pSS, 5% in sSS, and 15% in controls, and by ANAM were 29% in pSS and 10% in sSS (P > .05). Visuospatial/executive subdomain in the MoCA was different between the pSS and the control group (P = .005). We encountered a statistically significant difference between pSS patients and control scores from the program in 6 of the 7 domains tested by the ANAM.Conclusion: No difference was found in the prevalence of cognitive impairment between pSS subjects and controls by MoCA. Several subdomain scores differed between groups in both scales. Evaluation of cognitive disorders in patients with SS, even in early stages of the disease, seems advisable but the best strategy is yet to be elucidated.
- 30 June 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 23 (8) , 1019-1023
Cognitive dysfunction in Sjögren’s syndrome using the Montreal Cognitive Assessment Questionnaire and the Automated Neuropsychological Assessment Metrics: A cross‐sectional study
Aim: To describe the prevalence of cognitive impairment and the most affected cognitive domains, employing the Montreal Cognitive Assessment (MoCA) and the Automated Neuropsychological Assessment Metrics (ANAM) of a Latin American primary Sjögren's syndrome (pSS) cohort, and compare these patients to secondary Sjögren's syndrome (sSS) subjects and controls.Methods: This was a comparative cross‐sectional study of patients with a diagnosis of pSS who fulfilled the American‐European Consensus Group 2002 criteria and/or American College of Rheumatology/European League Against Rheumatism 2016 criteria; clinical information was evaluated prior to cognitive evaluation, which consisted of a single session in which the MoCA and ANAM were applied.Results: A total of 122 subjects were included in the analysis (51 pSS, 20 sSS and 51 controls); mean age of pSS was 56 years (SD 10.4), of which 47 (92.15%) were women. Moderate‐severe cognitive impairment by MoCA was 17% in pSS, 5% in sSS, and 15% in controls, and by ANAM were 29% in pSS and 10% in sSS (P > .05). Visuospatial/executive subdomain in the MoCA was different between the pSS and the control group (P = .005). We encountered a statistically significant difference between pSS patients and control scores from the program in 6 of the 7 domains tested by the ANAM.Conclusion: No difference was found in the prevalence of cognitive impairment between pSS subjects and controls by MoCA. Several subdomain scores differed between groups in both scales. Evaluation of cognitive disorders in patients with SS, even in early stages of the disease, seems advisable but the best strategy is yet to be elucidated.
- 5 May 2020
- Published by Springer Nature in Rheumatology International
- Vol. 40 (9) , 1433-1438
Anxiety and depression in reproductive age women with rheumatic diseases
Women in reproductive age with rheumatic diseases (RD) are especially vulnerable for depression and anxiety which negatively impacts the pregnancy, birth, and RD. The purpose of this study is to describe the frequency of anxiety and depression symptoms employing the Hospital Anxiety and Depression Scale (HADS) in women in reproductive age. We conducted an observational, single-center, cross-sectional, and descriptive study in reproductive-age, non-pregnant women without a prior psychiatric diagnosis. Differences between disease groups, subscale results, and disease activity were analyzed with the Chi square, Mann–Whitney U test, or Kruskal–Wallis test. A total of 100 women were included. Mean age was 35.3 years (SD = 10.07). The most frequent diagnosis was rheumatoid arthritis (RA) with 48, followed by systemic lupus erythematosus (SLE) with 30. A total of 66 (66%) patients had an abnormal HADS score (probable or possible cases) in either subscale. More than 50% of RA patients had an abnormal HADS score. We found an association between RA disease activity groups and total HADS score (p = 0.003). Furthermore, we found a statically significant association between RA activity groups and HADS anxiety subscales group classification (p = 0.01). No differences between disease activity groups of SLE or other diseases and HADS classification or total score was found (p = 0.277). A high frequency of probable or possible cases of depression and anxiety were recognized in reproductive-age women with RD. A high RA disease activity was associated with a high total HADS score and an increased presence of anxiety symptoms.
- 5 May 2020
- Published by Springer Nature in Rheumatology International
- Vol. 40 (9) , 1433-1438
Anxiety and depression in reproductive age women with rheumatic diseases
Women in reproductive age with rheumatic diseases (RD) are especially vulnerable for depression and anxiety which negatively impacts the pregnancy, birth, and RD. The purpose of this study is to describe the frequency of anxiety and depression symptoms employing the Hospital Anxiety and Depression Scale (HADS) in women in reproductive age. We conducted an observational, single-center, cross-sectional, and descriptive study in reproductive-age, non-pregnant women without a prior psychiatric diagnosis. Differences between disease groups, subscale results, and disease activity were analyzed with the Chi square, Mann–Whitney U test, or Kruskal–Wallis test. A total of 100 women were included. Mean age was 35.3 years (SD = 10.07). The most frequent diagnosis was rheumatoid arthritis (RA) with 48, followed by systemic lupus erythematosus (SLE) with 30. A total of 66 (66%) patients had an abnormal HADS score (probable or possible cases) in either subscale. More than 50% of RA patients had an abnormal HADS score. We found an association between RA disease activity groups and total HADS score (p = 0.003). Furthermore, we found a statically significant association between RA activity groups and HADS anxiety subscales group classification (p = 0.01). No differences between disease activity groups of SLE or other diseases and HADS classification or total score was found (p = 0.277). A high frequency of probable or possible cases of depression and anxiety were recognized in reproductive-age women with RD. A high RA disease activity was associated with a high total HADS score and an increased presence of anxiety symptoms.
- 14 March 2015
- Published by Springer Nature in Rheumatology International
- Vol. 35 (9) , 1555-1559
Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients
The incidence of tuberculosis (TB) in rheumatoid arthritis (RA) patients is up to four times higher when compared to the general population, but their risk increases with the use of TNF-a drugs. Appropriate screening of latent tuberculosis infection (LTBI) and proper management of such cases substantially reduce the incidence of active TB. Tuberculin skin test (TST) is a widely used method for the detection of LTBI. The time of diagnosis of RA as well as the age of the patient might modify the TST performance. We did an observational, comparative study of RA patients with early and established disease, with the objective to know the prevalence of LTBI using the TST and booster test; an induration ≥5 mm was considered reactive. We evaluated 143 patients (83 [58 %] early RA patients). We found 31.3 and 21.7 % TST positivity in early and established RA patients, respectively. With the use of booster test, the positivity increased to 46.5 and 28.8 %, respectively (p = 0.048, OR 1.33, 95 % CI 1.01-1.75). In conclusion, we found that TST and booster test increased LTBI detection in early RA patients, which may suggest that time of RA diagnosis might affect cellular immunity and therefore the TST response.
- 14 March 2015
- Published by Springer Nature in Rheumatology International
- Vol. 35 (9) , 1555-1559
Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients
The incidence of tuberculosis (TB) in rheumatoid arthritis (RA) patients is up to four times higher when compared to the general population, but their risk increases with the use of TNF-a drugs. Appropriate screening of latent tuberculosis infection (LTBI) and proper management of such cases substantially reduce the incidence of active TB. Tuberculin skin test (TST) is a widely used method for the detection of LTBI. The time of diagnosis of RA as well as the age of the patient might modify the TST performance. We did an observational, comparative study of RA patients with early and established disease, with the objective to know the prevalence of LTBI using the TST and booster test; an induration ≥5 mm was considered reactive. We evaluated 143 patients (83 [58 %] early RA patients). We found 31.3 and 21.7 % TST positivity in early and established RA patients, respectively. With the use of booster test, the positivity increased to 46.5 and 28.8 %, respectively (p = 0.048, OR 1.33, 95 % CI 1.01-1.75). In conclusion, we found that TST and booster test increased LTBI detection in early RA patients, which may suggest that time of RA diagnosis might affect cellular immunity and therefore the TST response.